LSV Asset Management
HRMY icon

LSV Asset Management’s Harmony Biosciences HRMY Stock Holding History

LSV Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75M Buy
2,061,242
+36,099
+2% +$1.14M 0.14% 200
2026
Q1 		$56.7M Buy
2,025,143
+368,050
+22% +$12.1M 0.12% 208
2025
Q4 		$62M Buy
1,657,093
+62,200
+4% +$2.05M 0.14% 194
2025
Q3 		$44M Buy
1,594,893
+106,391
+7% +$3.66M 0.1% 221
2025
Q2 		$47M Buy
1,488,502
+293,541
+25% +$9.44M 0.11% 212
2025
Q1 		$39.7M Buy
1,194,961
+238,744
+25% +$8.56M 0.1% 224
2024
Q4 		$32.9M Buy
956,217
+184,026
+24% +$6.32M 0.08% 259
2024
Q3 		$30.9M Buy
772,191
+193,945
+34% +$6.81M 0.07% 270
2024
Q2 		$17.4M Buy
578,246
+243,100
+73% +$7.31M 0.04% 349
2024
Q1 		$11.3M Buy
335,146
+260,093
+347% +$8.35M 0.02% 421
2023
Q4 		$2.42M Buy
+75,053
New +$2.09M 0.01% 594

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

LSV Asset Management's HRMY Position: Q2 2026 in Review

LSV Asset Management increased its Harmony Biosciences (HRMY) stake by 1.8% in Q2 2026, buying an estimated $1.14M and bringing the position to 2,061,242 shares worth $75M. The position accounts for 0.14% of the portfolio, ranked #200.

LSV Asset Management first reported a position in HRMY in Q4 2023 and has held it in 11 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • LSV Asset Management held 2,061,242 shares of Harmony Biosciences worth $75M as of Q2 2026.
  • LSV Asset Management bought 36,099 Harmony Biosciences shares in Q2 2026, an estimated $1.14M.
  • Harmony Biosciences made up 0.14% of LSV Asset Management's portfolio in Q2 2026, its #200 holding.
  • LSV Asset Management first reported a position in Harmony Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.